Amivantamab Plus Chemotherapy vs Chemotherapy as First-line Treatment in EGFR Exon 20 Insertion–Mutated Advanced NSCLC: Primary Results From PAPILLON, a Randomized Phase 3 Global Study | OncLive
13:44
Amivantamab Plus Chemotherapy vs Chemotherapy as First-line Treatment in EGFR Exon 20 Insertion–Mutated Advanced NSCLC: Primary Results From PAPILLON, a Randomized Phase 3 Global Study | OncLive
Nov 30, 2023
onclive.com
PAPILLON: amivantamab plus chemotherapy in NSCLC with EGFR exon 20 insertions
2:07
PAPILLON: amivantamab plus chemotherapy in NSCLC with EGFR exon 20 insertions
421 viewsMay 13, 2024
YouTubeVJOncology
Treatment Options for EGFR-Mutated Lung Cancer: Amivantamab + Lazertinib - 2024 Lung Cancer OncTalk
5:11
Treatment Options for EGFR-Mutated Lung Cancer: Amivantamab + Lazertinib - 2024 Lung Cancer OncTalk
751 viewsJan 30, 2025
YouTubeGlobal Resource for Advancing Cancer Education
Efficacy of Amivanatamab to Treat Left-Sided RAS/BRAF Wild-Type Metastatic Colorectal Cancer
3:49
Efficacy of Amivanatamab to Treat Left-Sided RAS/BRAF Wild-Type Metastatic Colorectal Cancer
278 views10 months ago
YouTubeCheckRare
Amivantamab plus lazertinib is a new standard for EGFR-mutant NSCLC
3:50
Amivantamab plus lazertinib is a new standard for EGFR-mutant NSCLC
976 viewsOct 11, 2024
YouTubeVJOncology
Results From Amivanatamab Clinical Trial for Metastatic Colorectal Cancer
5:39
Results From Amivanatamab Clinical Trial for Metastatic Colorectal Cancer
174 views9 months ago
YouTubeCheckRare
New Insights From the MARIPOSA Trial: Amivantamab Plus Lazertinib for EGFR-Mutated NSCLC
2:54
New Insights From the MARIPOSA Trial: Amivantamab Plus Lazertinib for EGFR-Mutated NSCLC
961 views11 months ago
YouTubeOncUpdates: Latest Oncology Insights
2:15
Amivantamab is approved as second-line therapy for NSCLC with EGFR exon 20 insertions. Preliminary data showed safety and antitumor activity of amivantamab when combined with chemotherapy. New research findings are summarized in this short video. https://nej.md/3rYHf7e | The New England Journal of Medicine
1.6K viewsNov 30, 2023
FacebookThe New England Journal of Medicine
16:45
Amivantamab in combination with lazertinib for osimertinib-relapsed, chemo-naïve EGFRm NSCLC
1.8K viewsAug 4, 2021
YouTubeecancer
11:42
MARIPOSA-2: Amivantamab ± Lazertinib + Chemo After Osimertinib in EGFR+ NSCLC | Phase III
80 views10 months ago
YouTubeCancer Research and Statistic Foundation
4:14
IASLC World Conference on Lung Cancer: Nursing Insights for Amivantamab and Lazertinib Toxicities
55 views7 months ago
YouTubeCancerNursingToday
2:04
MARIPOSA-2: amivantamab + chemo (± lazertinib) vs chemo in EGFR-mutated NSCLC post-osimertinib
929 viewsOct 30, 2023
YouTubeVJOncology
11:35
Amivantamab for Recurrent or Metastatic Adenoid Cystic Carcinoma
119 views1 month ago
YouTubeJAMA Network
3:01
Dermatologic adverse events in the treatment of NSCLC with amivantamab plus lazertinib significa...
47 views8 months ago
YouTubeecancer
Dr Reckamp on Amivantamab in EGFR Exon 20–Mutated NSCLC
1:02
Find in video from 00:46How does it work in combination with chemotherapy?
Dr Reckamp on Amivantamab in EGFR Exon 20–Mutated NSCLC
415 viewsJul 27, 2024
YouTubeOncLive
1:11
Evaluating the benefits of subcutaneous amivantamab in EGFR-m NSCLC
143 viewsSep 25, 2024
YouTubeVJOncology
3:21
Post-progression analysis of MARIPOSA-2: amivantamab + chemo in EGFR+ NSCLC
479 viewsMay 10, 2024
YouTubeVJOncology
Dr Besse on Mechanisms of Acquired Resistance in EGFR+ Advanced NSCLC
1:10
Find in video from 00:11Mechanism of Resistance of Amab Plus Laser
Dr Besse on Mechanisms of Acquired Resistance in EGFR+ Ad…
166 viewsOct 5, 2024
YouTubeOncLive
5:12
Subcutaneous Amivantamab Reshapes Frontline EGFR-Mutant NSCLC Care
589 views2 months ago
YouTubeOncUpdates: Latest Oncology Insights
20:46
MARIPOSA - Combination of Amivantamab & Lazertinib for Common EGFR Mutations in NSCLC
3.7K views11 months ago
YouTubeOncBrothers: Practice-Changing Cancer Discu…
4:01
OrigAMI-4: amivantamab monotherapy in previously treated R/M HNSCC
76 views6 months ago
YouTubeVJOncology
6:34
Targeted Therapies in EGFR-Mutated NSCLC: Managing Treatment-Related AEs
813 views11 months ago
YouTubeOncUpdates: Latest Oncology Insights
MARIPOSA-2: second interim OS of amivantamab and chemotherapy in EGFR-m NSCLC
3:17
Find in video from 01:13Survival Benefit for Chemotherapy
MARIPOSA-2: second interim OS of amivantamab and chemotherapy i…
470 viewsSep 16, 2024
YouTubeVJOncology
PAPILLON Study - Amivantamab Chemo vs. Chemo as 1L Treatment in EGFR Exon 20 Insertion-Mutated Advanced NSCLC
Feb 12, 2024
vumedi.com
17:40
Challenging Cases with Metastatic EGFR Mutated Non-Small Cell Lung Cancer with Dr. Eric Singhi
4.5K views6 months ago
YouTubeOncBrothers: Practice-Changing Cancer Discu…
0:55
MARIPOSA Update - Amivantamab + Lazertinib in 1L EGFR mutated metastatic NSCLC.
861 viewsJun 24, 2024
YouTubeOncBrothers: Practice-Changing Cancer Discu…
2:08
MARIPOSA: mechanisms of resistance to 1L amivantamab + lazertinib in pts with EGFR-m NSCLC
287 viewsSep 14, 2024
YouTubeVJOncology
5:18
Expert video report on amivantamab in combination therapy for 1L treatment in EGFRm, advanced NSCLC
2.4K viewsOct 30, 2023
YouTubeEuropean Society for Medical Oncology (ESMO)
2:32
Management of AEs from amivantamab and lazertinib for EGFR-m NSCLC
167 viewsSep 25, 2024
YouTubeVJOncology
2:25
PALOMA-2: subcutaneous amivantamab Q4W and lazertinib in EGFR+ NSCLC
39 views8 months ago
YouTubeVJOncology
See more